Professor Christoph Lange, MD - Program Chair

Professor Christoph Lange, MD - Program Chair


Medical Director/Clinical Director
Research Center Borstel
Borstel, Germany

Related Videos

Completing the Journey from Diagnosis to Cure in MAC Lung Disease<br><sub>Translating Trial-Based Results to Real World, Side Effect-Mitigating Patient Care</sub> Video

Completing the Journey from Diagnosis to Cure in MAC Lung Disease
Translating Trial-Based Results to Real World, Side Effect-Mitigating Patient Care

All NTM Patients Are Not Created Equal<br><sub>Focus on Prompt Intervention, Individualized Management, and Risk Severity-Directed Treatment for Refractory MAC Lung Disease</sub> Video

All NTM Patients Are Not Created Equal
Focus on Prompt Intervention, Individualized Management, and Risk Severity-Directed Treatment for Refractory MAC Lung Disease

Real World Case Management of MAC Lung Disease: Analyzing, Evaluating, and Managing Advanced Disease<br><sub>Matching Treatments with Patient Risk Factors and Optimizing Regimen Adherence with Novel Inhaled Antimicrobial Formulations</sub> Video

Real World Case Management of MAC Lung Disease: Analyzing, Evaluating, and Managing Advanced Disease
Matching Treatments with Patient Risk Factors and Optimizing Regimen Adherence with Novel Inhaled Antimicrobial Formulations

The Challenging Morbidity, Risk, and Therapeutic Continuum of MAC Lung Disease<br><sub>What Have We Learned from the ERS Treatment Guideline, Real World Experience, and Recent Trials Focused on High Risk/Refractory MAC Lung Disease?</sub> Video

The Challenging Morbidity, Risk, and Therapeutic Continuum of MAC Lung Disease
What Have We Learned from the ERS Treatment Guideline, Real World Experience, and Recent Trials Focused on High Risk/Refractory MAC Lung Disease?

Real World Case Management: Evaluating and Managing Patients with Advanced MAC Lung Disease/Refractory Features Video

Real World Case Management: Evaluating and Managing Patients with Advanced MAC Lung Disease/Refractory Features

Focus on Indications for and Optimizing Regimen Adherence with Novel Inhaled Antimicrobial Formulations

Evidence for Prompt, Intensive Intervention in Risk Appropriate Patients with MAC Lung Disease Video

Evidence for Prompt, Intensive Intervention in Risk Appropriate Patients with MAC Lung Disease

Practical, Real World Application of Guidelines at the Front Lines of Patient Care for MAC Pulmonary Disease

Patient Identification, Selection, and Timing of Antimicrobial Treatment in the Context of Year 2020 ERS/ATS/ESCMID/IDSA Guideline-Based Therapy for MAC Lung Disease Video

Patient Identification, Selection, and Timing of Antimicrobial Treatment in the Context of Year 2020 ERS/ATS/ESCMID/IDSA Guideline-Based Therapy for MAC Lung Disease

New Guidance for Treatment of High Risk and Refractory Disease

The Mandate for Individualized Care in Persons with NTM Lung Disease and Limited Options<br><sub>When and How to Intensify Antimicrobial Therapies Based on Clinical Presentation and Microbial Testing</sub> Video

The Mandate for Individualized Care in Persons with NTM Lung Disease and Limited Options
When and How to Intensify Antimicrobial Therapies Based on Clinical Presentation and Microbial Testing

Applying New Trial-Based Evidence, Guidelines, and Individualized Approaches to Real World Management for MAC Lung Disease Video

Applying New Trial-Based Evidence, Guidelines, and Individualized Approaches to Real World Management for MAC Lung Disease